Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Captor Therapeutics Pretax Margin % Related Terms
Captor Therapeutics Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Captor Therapeutics's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:CTX vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, Captor Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Captor Therapeutics Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Captor Therapeutics's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Captor Therapeutics's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Captor Therapeutics (WAR:CTX) has a Pretax Margin % of -3,459.76% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Captor Therapeutics and its competitors. According to the industry distribution chart, Captor Therapeutics ranks #785 out of 941 companies in the Biotechnology industry, placing it in the top 83.4%.
Is Captor Therapeutics' Pretax Margin % too high?
Captor Therapeutics' current Pretax Margin % is -3,459.76%. Based on the distribution chart, Captor Therapeutics ranks #785 out of 941 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Captor Therapeutics has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Captor Therapeutics' Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Captor Therapeutics ranks #785 out of 941 companies for Pretax Margin %. This places Captor Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Captor Therapeutics and its competitors. Captor Therapeutics's current Pretax Margin % is -3,459.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Captor Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Captor Therapeutics (WAR:CTX) is currently considered Significantly Overvalued. The stock's GF Value™ is zł10.13, compared to a current price of zł73.50 — trading 625.6% above its estimated fair value. The current Pretax Margin % is -3,459.76%. Captor Therapeutics' overall GF Score™ is 38/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Captor Therapeutics (WAR:CTX), the current Pretax Margin % is -3,459.76% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Captor Therapeutics (WAR:CTX) Overvalued in 2026?
Based on GuruFocus' analysis, Captor Therapeutics stock appears to be overvalued.
The current stock price of zł73.50 is trading 625.6% above its estimated GF Value™ of zł10.13.
GuruFocus considers Captor Therapeutics to be Significantly Overvalued.
Key valuation signals for WAR:CTX:
Pretax Margin %: -3,459.76%
GF Value™: zł10.13 vs. price of zł73.50 (625.6% above fair value)
No single metric tells the full story. See the WAR:CTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Captor Therapeutics SA is a biopharmaceutical company. It is focused on development of protein degradation drugs for cancer and autoimmune diseases, which have limited or no known treatment options.
38GF Score
Get the complete analysis for WAR:CTX
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:CTX has been successfully added to your 
